ASTRO 2024

Questions discussed in this category

How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?

Are you routinely offering a 16-fraction course of hypofractionated PMRT for patients undergoing breast reconstruction versus a traditional 25-fractio...

4 Answers available

As PARTIQoL was a negative study, what is the current role for proton therapy in the management of prostate cancer patients?

The study showed no benefit in terms of cancer control or toxicity. There was a significant finding of worse sexual function, but this was deemed to b...

2 Answers available

Papers discussed in this category

Radiation oncology (London, England), 2015-10-24

Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer.

J Clin Oncol, 2021 Jan 20

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.

International journal of radiation oncology, biology, physics, 2024 Sep 01

Point: Rectal Spacer Use is Recommended for All Prostate Cancer Radiation Therapy Fractionation Regimens.

International journal of radiation oncology, biology, physics, 2024 Sep 01

Counterpoint: The Perplexing Prevalence of Hydrogel Spacer Devices: We Simply Don't Need Them.

International journal of radiation oncology, biology, physics, 2024 Sep 26

Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.

The Prostate, 2023 Mar 22

Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial.

Related Topics